DGAP-News: INJEX Pharma AG signs exclusive Distribution Agreement for USA / Minimum Purchase of 70,000 INJEX30 Systems and 25,000 SHIREEN Beauty Kits in the first year
(firmenpresse) - DGAP-News: INJEX Pharma AG / Key word(s): Contract
INJEX Pharma AG signs exclusive Distribution Agreement for USA /
Minimum Purchase of 70,000 INJEX30 Systems and 25,000 SHIREEN Beauty
Kits in the first year
04.09.2012 / 15:37
---------------------------------------------------------------------
INJEX Pharma AG signs exclusive Distribution Agreement for USA / Minimum
Purchase of 70,000 INJEX30 Systems and 25,000 SHIREEN Beauty Kits in the
first year
INJEX Pharma AG ISIN: DE000A0STYL7
Berlin, 04 September 2012
Berlin - Newly founded '21 Medical Technologies LLC.,' (21 MT) located in
Fort Lauderdale, Florida, will exclusively market and distribute INJEX30
Systems in the United States. INJEX30 syringes without a needle may be used
in multiple medical, cosmetic and anesthetic applications and marketed via
traditional pharmaceutical and emerging life science modalities. INJEX30
targeted disease states and delivery systems include diabetes, local and
dental anesthetics, allergy and fertility treatments, vaccinations,
erectile dysfunction and growth hormones. '21 MT' is a perfect partner in
the US and it's an exciting time for INJEX Pharma AG as we continue to
execute on our global mission while simultaneously introducing the SHIREEN
Beauty Kit utilizing a 'Poring method' in the United States.' Andy Rösch,
CEO INJEX Pharma AG.
The signed distributor agreement includes a minimum volume of 70,000
INJEX30 Systems, 25,000 SHIREEN Beauty Kits and 300,000 SHIREEN Fluid
Units. The First shipment will commence during the month of September.
'Product launches in the United States must be carefully orchestrated
across many modalities including direct to the consumer. The United
States' healthcare industry appears to be in early stages of its
transformation which presents an opportune time to align our innovative
technology with a 'High profile personality.' '21 MT' has the ability to
raise immediate awareness for both INJEX30 Systems and SHIREEN Beauty Kits
through its media reach and seasoned team of professionals. We look
forward to working closely with '21 MT' as they prepare to deploy
significant resources across modalities. This multi-faceted approach will
be necessary to build brand awareness with an emphasis on 'service
excellence.' This agreement is a 'Home run' for the end users who will
benefit from a syringe delivery system without a needle.' Sylwin Grinman,
Director International Sales and Marketing at INJEX Pharma AG.
'We are excited to begin marketing our innovative 'Poring method' with
SHIREEN Beauty Kits in the world's biggest beauty market. '21 MT' was
founded with an appreciation for challenges when dealing with big markets
and we are comfortable '21 MT' will exceed distribution expectations and
establish new benchmarks for 'service excellence' in this industry. We
will be increasing our production capacities in the short-term and
developing necessary logistical contingencies to meet future demand. '21
MT' will consummate this agreement in the days ahead, with payments on the
way, triggering exclusivity, as terms for initial shipments are met.
Shortly thereafter, we expect to conduct a press conference with 21 Medical
Technologies LLC, elaborating on our vision, steps for executing in the US
and defining details related tothis agreement.' Andy Rösch, CEO INJEX
Pharma AG.
Contact:
Andy Rösch
CEO
INJEX Pharma AG
Buckower Damm 114
12349 Berlin
Tel.: +49-3053096768
andy.roesch(at)injex.com
www.injex.com
Sylwin Grinman
Managing Director
INJEX Pharma USA
1922 NE 119 RD
North Miami Beach - FL - 33181
USA
Tel.: +1-7865121963
sylwin(at)injex.com
End of Corporate News
---------------------------------------------------------------------
04.09.2012 Dissemination of a Corporate News, transmitted by DGAP - a
company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
184146 04.09.2012
Themen in dieser Pressemitteilung:
injex-pharma-ag-signs-exclusive-distribution-agreement-for-usa-minimum-purchase-of-70
000-injex30-systems-and-25
000-shireen-beauty-kits-in-the-first-year
Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: EquityStory
" alt="Homestake Resource Corporation Enters Into Property Option and Share Purchase Agreement with Agnico-Eagle Mines LimitedDatum: 04.09.2012 - 15:37 Uhr
Sprache: Deutsch
News-ID 179933
Anzahl Zeichen: 0
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 353 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: INJEX Pharma AG signs exclusive Distribution Agreement for USA / Minimum Purchase of 70,000 INJEX30 Systems and 25,000 SHIREEN Beauty Kits in the first year"
steht unter der journalistisch-redaktionellen Verantwortung von
INJEX Pharma AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
